First Anti-PD-1 Regimen Approved in China for First-Line Treatment of Advanced Esophageal or GEJ Cancer, Regardless of Histology or PD-L1 Expression
KEYTRUDA Is Now Approved for Eight Indications Across Five Different Types of Cancer in China
https://finance.yahoo.com/news/merck-keytruda-pembrolizumab-approved-china-104500852.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.